GOLOMB GERSHON (Total 154 Patents Found)

The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeut...
The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or m...
The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedl...
A phospholipid conjugate according to the general formula (I) or according to the general formula (II) for use in the treatment or prevention of a disorder selected from skin hypersensitivity, respiratory disease, eye disorder, and inflammatory bowel disease....
Bisphosphonate compounds are of the Formula (I): ##STR1## wherein Y is ═O or ═N--OH and n is from 3 to 24, and further wherein when Y is ═O, (i) R 1 is hydrogen and R 2 is sodium, or (ii) R 1 is sodium and R 2 is methyl, and when Y is ═N--OH, R 1 is sodium and R 2 is methyl....
A method of treating or preventing restenosis by administering to an individual an effective amount of an active compound which depletes and/or inhibits blood monocytes or macrophages thereby treating restenosis. A method of inhibiting the activity or production of cytokines or growth factors associated with vascular r...
The present invention generally relates to polymers and particles, such as nanoparticles. The particles and polymers generally include one or more buffering components. Additionally, the particles and polymers may include two or more components that impart useful properties (functionalities). The particles and polymers...
The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeut...
The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeut...
Novel bisphosphonates comprise compounds of the formula (I) ##STR1## wherein m and l are independently 1 or 2; R 1 represents hydrogen, a lower alkyl group, or an alkali metal cation; R 2 represents hydrogen, a lower alkyl group or an alkali metal cation; Y represents ═0 or ═N--OH, or --OH; and X represents --(CH...
An isometric enriched tyrphostin of a general formula: wherein, for Compound I, the tyrphostin is enriched either for R 6 at position 6 or for R 6 at position 7, or, for Compound II, the tyrphostin is enriched either for R 6 at position 6 or for R 6 at position 8. Further disclosed ...
A method for preparing hydroxamic acid polymers from primary amide polymers wherein polyvinyl monomers such as polyacrylamide are reacted with hydroxyl amine in aqueous solution at room temperature. The low reaction temperature is crucial to producing a high yield (70%) of polymer with hydroxamic acid groups and having...
A method of treating an acute myocardial infarction by administering to an individual an effective amount of a formulation which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction. The formulation co...
La présente invention concerne des composés PDGF inhibiteurs du récepteur de la kinase et faisant partie de la famille des quinoxalines, leurs procédés de synthèse et de confinement par des préparations pharmaceutiques à libération lente, ainsi que leur utilisation dans le traitement des maladies ou des affect...
Un implant en biomatériaux, dérivés de préférence de tissus animaux traités au glutaraldéhyde, est lié par covalence à un composé qui donne une charge positive nette à l'implant. L'implant est de préférence traité avec un acide polyaminé ayant des groupes amino libres afin de donner la charge pos...
L'invention concerne des composés bisphosphonates, leur préparation et des compositions pharmaceutiques contenant de tels composés en tant qu'ingrédients actifs. Ces compositions s'administrent généralement par voie orale et elles permettent de traiter efficacement les anomalies du métabolisme du cal...
The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedl...
L'invention concerne une nanoparticule capable d'introduire une molécule encapsulée dans une cellule vivante. La nanoparticule comprend un support d'encapsulation et une séquence homologue isolée d'acides nucléiques. Le support d'encapsulation est principalement polymère. Les nanoparticules li...
Hydroxamic acid polymers which are comprised of hydroxamic groups and carboxylic acid groups wherein the carboxylic acid groups constitute less than about 3% of the functional groups. The polymers hereof are also especially useful in biomedical applications because, for example, the low concentration of carboxyli...
A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject....
The present invention provides a compound of the following formula (I): R3-NH-C(=X)-P(=O)OR1OR2 including pharmaceutically acceptable salts, solvates, hydrates and polymorphs of the compounds of formula I, as well as geometrical isomers and optically active forms of the compounds of formula I and pharmaceutically accep...
The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeut...
A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further ...
La présente invention concerne des composés PDGF inhibiteurs du récepteur de la kinase et faisant partie de la famille des quinoxalines, leurs procédés de synthèse et de confinement par des préparations pharmaceutiques à libération lente, ainsi que leur utilisation dans le traitement des maladies ou des affect...
A method of treating or preventing restenosis by administering to an individual an effective amount of an active compound which depletes and/or inhibits blood monocytes or macrophages thereby treating restenosis. A method of inhibiting the activity or production of cytokines or growth factors associated with vascular r...
A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cel...
Partículas que comprenden un bisfosfonato para inhibir células fagocíticas para su uso en el tratamiento de la endometriosis, en las que dicho bisfosfonato comprende un compuesto que tiene la siguiente fórmula I: en la que R1 es H, OH o un grupo halógeno y; R2 es halógeno; alquilo C1-C10 lineal o ramificado o alq...
La présente invention se rapporte à des procédés et des compositions conçus pour la prophylaxie, la réduction, le traitement ou la prise en charge de l'hypersensibilité aiguë liée à l'activation du complément, également appelée pseudoallergie à médiation C (CARPA), provoquée par l'administra...
The present invention provides a compound of the following formula I: R 3 —NH—C(═X)—P(═O)OR 1 OR 2 including pharmaceutically acceptable salts, solvates, hydrates and polymorphs of the compounds of formula I, as well as geometrical isomers and optically active forms of the compounds of formula I and phar...
本发明提供了下式(I)的化合物:R<sup>3</sup>-NH-C(=X)-P(=O)OR<sup>1</sup>OR<sup>2</sup>,其包括该式I化合物的药学上可接受的盐、溶剂化物、水合物和多晶型物,该式I化合物的几何异构体和旋光体,以及所述异构体和旋光体...
Un isómero de tirfostina sustancialmente purificado de la **fórmula** en la que 4, 5, 6, 7, 8 y 9 indican posiciones del anillo aromático terminal de 6 eslabones; A, D, X e Y son en cada caso un nitrógeno; B es un carbono; la línea de puntos en el anillo de cinco eslabones significa que el enlace A--B o el enlace ...
A method for treating patients having calcium related disorders includes using di- or tripeptide derivatives of bisphosphonates to enhance oral bioavailability of such compounds....
Cette invention concerne, de manière générale, des polymères et des particules, telles que des nanoparticules. Les particules et les polymères comprennent, de manière générale, un ou plusieurs composants de tamponnage. De plus, les particules et les polymères peuvent comprendre deux composants ou plus qui conf...
L'invention concerne des procédés et des compositions conçus de manière à prévenir, réduire, traiter ou gérer une lésion d'ischémie-reperfusion. Les procédés de l'invention consistent à administrer une quantité efficace d'une formulation thérapeutique contenant un ou plusieurs composés a...
The invention provides a compound according to the formula: (see formula I) wherein R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 c...
A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject....